Konruns(SH:603590) Xin Lang Cai Jing·2025-10-16 02:14Core Viewpoint - Kangchen Pharmaceutical experienced a 5.03% increase in stock price, reaching 51.58 CNY per share, with a total market capitalization of 8.22 billion CNY as of October 16 [1] Group 1: Company Overview - Beijing Kangchen Pharmaceutical Co., Ltd. was established on September 3, 2003, and went public on August 27, 2018 [1] - The company focuses on innovative drug research and development, guided by clinical needs, integrating research, production, and sales [1] - The main revenue sources are: Suling (70.77%), Salmon Calcitonin (29.15%), and others (0.09%) [1] Group 2: Fund Holdings - Yongying Fund has a significant holding in Kangchen Pharmaceutical, with Yongying Medical Health A (008618) owning 163,200 shares, representing 5.11% of the fund's net value, making it the sixth-largest holding [2] - The fund has generated an estimated floating profit of approximately 403,100 CNY today [2] - Yongying Medical Health A was established on May 20, 2020, with a current scale of 24.18 million CNY and a year-to-date return of 15.15% [2]